Status:
COMPLETED
ECLS Versus IMPELLA™ as Bridge to LVAD (ECI-BLAD)
Lead Sponsor:
University Hospital, Bordeaux
Conditions:
Cardiogenic Shock
End-stage Heart Failure
Eligibility:
All Genders
18+ years
Brief Summary
In this retrospective observational multicenter study the authors tested the hypothesis that the use of IMPELLA™ pump as bridge to bridge, by giving the opportunity of active rehabilitation, should im...
Detailed Description
End stage heart failure patients admitted in Intensive Care Unit (ICU) for refractory cardiogenic shock requiring short-term mechanical circulatory support as a bridge to a long-term LVAD might benefi...
Eligibility Criteria
Inclusion
- patients supported with IMPELLA™ or ECLS for refractory cardiogenic shock as a bridge to long duration LVAD
Exclusion
- Patient refusing to give access to their medical chart
- Guardianship and curactorship
- Deprived of liberty
- short term mechanical circulatory system weaned before LVAD implantation
Key Trial Info
Start Date :
January 20 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 21 2021
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT04480151
Start Date
January 20 2021
End Date
April 21 2021
Last Update
July 7 2021
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Dijon-Bourgoigne
Dijon, France, 21079
2
CHU de Montpellier
Montpellier, France, 34295
3
CHU de Bordeaux
Pessac, France, 33604
4
CHU de Rennes
Rennes, France, 35000